A substance from a fungus that infects caterpillars could offer new treatment hope for sufferers…
View More Caterpillars could hold the secret to new treatment for osteoarthritis
Home » Medications »
Dramatic shifts in first-time opioid prescriptions bring hope, concern
A national call for restraint in opioid prescribing has yielded dramatic progress in clinician prescribing…
View More Dramatic shifts in first-time opioid prescriptions bring hope, concern
Drug company used rap video to push for higher doses, sales
Employees at a drug company accused of bribing doctors rapped and danced around a person…
View More Drug company used rap video to push for higher doses, sales
Oily formulations for efficient oral medications
A new recipe for pills and tablets that includes oils and tiny porous particles can…
View More Oily formulations for efficient oral medications
Endocannabinoid system, a target to improve cognitive disorders in models of Down syndrome
A study by the Neuropharmacology Laboratory-NeuroPhar of the Department of Experimental and Health Sciences (DCEXS)…
View More Endocannabinoid system, a target to improve cognitive disorders in models of Down syndrome
FDA Approves Use of 0.5 mL Dose of Fluzone Quadrivalent (influenza vaccine) in Children as Young as 6 Months of Age
BRIDGEWATER, N.J., Jan. 23, 2019 /PRNewswire/ — The U.S. Food and Drug Administration has approved…
View More FDA Approves Use of 0.5 mL Dose of Fluzone Quadrivalent (influenza vaccine) in Children as Young as 6 Months of Age
Proteus Digital Health Launches Digital Oncology Medicines to Improve Patient Outcomes
January 17, 2019 – REDWOOD CITY, Calif. and MINNEAPOLIS, Minn. – Proteus Digital Health®, Inc.,…
View More Proteus Digital Health Launches Digital Oncology Medicines to Improve Patient Outcomes
Loxo Oncology Announces Initiation of Phase 1/2 Clinical Trial for Highly Selective, Non-Covalent BTK Inhibitor, LOXO-305
STAMFORD, Conn., Dec. 21, 2018 (GLOBE NEWSWIRE) — Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company…
View More Loxo Oncology Announces Initiation of Phase 1/2 Clinical Trial for Highly Selective, Non-Covalent BTK Inhibitor, LOXO-305
FDA Approves Vaxelis
BRIDGEWATER, N.J. and KENILWORTH, N.J. – December 26, 2018 –The U.S. Food and Drug Administration…
View More FDA Approves Vaxelis